Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2C8 | P10632 | 1/20 | 0.38 |
| ▸ | SERPINE1 | P05121 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | DNMT1 | P26358 | 3/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.30 |
| ▸ | NOX4 | Q9NPH5 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL833251 | 0.89 | CYP2C8 (0.36) | CYP2C8SERPINE1KMT2ADNMT1SIGMAR1 | |
| SCHEMBL832113 | 0.85 | CYP2C8 (0.38) | CYP2C8SERPINE1KMT2ADNMT1MDM2 | |
| SCHEMBL12665817 | 0.83 | CYP2C8 (0.40) | CYP2C8KMT2ANOX4 | |
| SCHEMBL831906 | 0.83 | SCN9A (0.38) | CYP2C8KMT2A | |
| SCHEMBL12665395 | 0.81 | CYP2C8 (0.46) | CYP2C8SERPINE1KMT2ANOX4 | |
| SCHEMBL831390 | 0.80 | CYP2C8 (0.39) | CYP2C8KMT2A | |
| SCHEMBL832000 | 0.80 | CYP2C8 (0.38) | CYP2C8SERPINE1KMT2ADNMT1 | |
| SCHEMBL12665807 | 0.79 | CYP2C8 (0.43) | CYP2C8KMT2ANOX4 | |
| SCHEMBL831480 | 0.79 | CYP2C8 (0.39) | CYP2C8KMT2A | |
| SCHEMBL832072 | 0.79 | CYP2C8 (0.36) | CYP2C8KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8143305-B2 | 2,3-substituted indole derivatives for treating viral infections | SCHERING CORPORATION (US) | 2012-03-27 | — | — | US | disclosed |
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | MERCK SHARP & DOHME CORP. | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110033417-A1 | 2,3-SUBSTITUTED INDOLE DERIVATIVES FOR TREATING VIRAL INFECTIONS | IDO2, IDO1, IRF3 | CYP2C8 847/4885SERPINE1 3846/4885KMT2A 321/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.